Immunocore Holdings Total Assets 2020-2021 | IMCR

Immunocore Holdings total assets from 2020 to 2021. Total assets can be defined as the sum of all assets on a company's balance sheet.
Immunocore Holdings Annual Total Assets
(Millions of US $)
2020 $253
2019 $237
Immunocore Holdings Quarterly Total Assets
(Millions of US $)
2021-09-30 $456
2021-06-30 $493
2021-03-31 $526
2020-12-31 $253
2019-12-31 $237
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.990B $0.039B
Immunocore Holdings plc is a late-stage biotechnology company. It engages in development of a novel class of T cell receptor bispecific immunotherapies designed to treat diseases, including cancer, infectious and autoimmune disease. Immunocore Holdings plc is based in Abingdon, the United Kingdom.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $144.122B 9.11
Bio-Rad Laboratories (BIO.B) United States $18.677B 37.90
QIAGEN (QGEN) Netherlands $11.053B 18.72
Biohaven Pharmaceutical Holding (BHVN) United States $8.002B 0.00
Emergent Biosolutions (EBS) United States $2.809B 10.10
Arcus Biosciences (RCUS) United States $2.516B 0.00
Myovant Sciences (MYOV) United Kingdom $1.432B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.186B 0.00
Zymeworks (ZYME) Canada $0.697B 0.00
Ambrx Biopharma (AMAM) United States $0.230B 0.00
SQZ Biotechnologies (SQZ) United States $0.229B 0.00
Enzo Biochem (ENZ) United States $0.160B 20.69